Related Experiment Video

Updated: Jun 27, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.6K

Extracellular vesicles-powered immunotherapy: Unleashing the potential for safer and more effective cancer treatment

Pratiksha Tiwari1, Krishna Yadav2, Ravi Prakash Shukla2

  • 1Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India; Jawaharlal Nehru University, New Delhi, India.

Archives of Biochemistry and Biophysics
|May 2, 2024
PubMed

Insights

Extracellular vesicles (EVs) offer a promising way to improve cancer immunotherapy (OIMTs) by enhancing effectiveness and reducing side effects. Integrating nanomedicines with EVs can overcome current challenges and advance OIMTs in clinical practice.

Area of Science:

  • Oncology
  • Immunology
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Onco-immunotherapies (OIMTs) represent significant advancements in cancer treatment, with some approved and others in development.
  • Challenges remain in optimizing OIMT efficacy and minimizing adverse effects for broader clinical application.
  • Improving response rates across various immunotherapy modalities is crucial for maximizing patient benefits.

Purpose of the Study:

  • To discuss the integration of nanomedicines into OIMTs for enhanced therapeutic outcomes.
  • To highlight challenges associated with current anti-OIMT strategies and explore solutions.
  • To examine novel nanomedicine design considerations and innovative delivery systems for OIMTs.

Main Methods:

  • Review of current literature on Onco-immunotherapies (OIMTs) and nanomedicine delivery systems.
  • Exploration of extracellular vesicles (EVs) as nanocarriers for immunotherapy.
  • Discussion of biomimicry and natural biomaterial-based nanocarriers (NCs) for OIMT enhancement.
  • Analysis of challenges in translating OIMTs from preclinical research to clinical practice.

Main Results:

  • Extracellular vesicles (EVs) show potential as effective delivery systems for immunotherapies, enhancing efficacy and reducing side effects.
  • Nanomedicine integration offers a strategy to overcome limitations of current OIMT methods.
  • Innovative approaches like biomimicry and natural biomaterial-based nanocarriers (NCs) are emerging for improved immunotherapy delivery.
  • Significant challenges exist in the clinical translation of advanced nanotechnology-based OIMTs.

Conclusions:

  • Nanomedicines, particularly when utilizing extracellular vesicles (EVs) and other advanced nanocarriers, hold significant promise for improving Onco-immunotherapies (OIMTs).
  • Addressing design considerations and overcoming clinical translation hurdles are essential for realizing the full potential of nanomedicine-enhanced OIMTs.
  • Future research and development in nanotechnology are critical for advancing cancer treatment through more effective and safer immunotherapies.
Keywords:
CancerExosomesImmunotherapyNanocarrierTargetingVaccine delivery

More Related Videos

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

689
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
359
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K